Literature DB >> 1797092

Interaction of epidermal growth factor with vasoactive hormones in the regulation of phospholipase A2.

N Hack1, B Margolis, J Schlessinger, K Skorecki.   

Abstract

The interaction of growth factors with their receptors initiates a series of intracellular events that are of critical importance in the control of normal cell proliferation. In this regard considerable attention has focused on the coupling of phospholipase C-gamma to growth factor receptor tyrosine kinases. In contrast, the interaction of growth factors with phospholipase A2 has received less attention, most likely because the arachidonic acid release response has been considered to be an accompaniment of phospholipase C activation. Work from our laboratory using a well defined model system demonstrated a distinct coupling relationship of epidermal growth factor to phospholipase A2. This review focuses on the interaction of the epidermal growth factor receptor with phospholipases involved in both mitogenic and non-mitogenic responses and discusses their possible relation with vasoactive hormones.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1797092     DOI: 10.1515/jbcpp.1991.2.3.161

Source DB:  PubMed          Journal:  J Basic Clin Physiol Pharmacol        ISSN: 0792-6855


  3 in total

Review 1.  Transmembrane signaling in kidney health and disease.

Authors:  N Hack; A Schultz; P Clayman; H Goldberg; K L Skorecki
Journal:  Pediatr Nephrol       Date:  1995-08       Impact factor: 3.714

2.  Inhibitors of cytochrome P450 4A suppress angiogenic responses.

Authors:  Ping Chen; Meng Guo; Dana Wygle; Paul A Edwards; John R Falck; Richard J Roman; A Guillermo Scicli
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

3.  Epidermal growth factor and phorbol myristate acetate increase expression of the mRNA for cytosolic phospholipase A2 in glomerular mesangial cells.

Authors:  A P Maxwell; H J Goldberg; A H Tay; Z G Li; G S Arbus; K L Skorecki
Journal:  Biochem J       Date:  1993-11-01       Impact factor: 3.857

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.